Trial · NCT01945021
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 2 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 0 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 1 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 2 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 0 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 1 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Platelet Count Decreased: Baseline Grade 2 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Leukocytosis: Baseline Grade 0 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Leukocytosis: Baseline Grade 0 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 3 | 3 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 3 | 1 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Lymphocyte Count Increased: Baseline Grade 0 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Lymphocyte Count Increased: Baseline Grade 2 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Lymphocyte Count Decreased: Baseline Grade 0 to Worst Grade 3 | 4 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Lymphocyte Count Decreased: Baseline Grade 1 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Lymphocyte Count Decreased: Baseline Grade 2 to Worst Grade 3 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01945021/results?page=2